DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients

Information source: Cantonal Hospital of St. Gallen
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Colorectal Cancer

Intervention: 5FU and capecitabine (Xeloda®) dosing based on DPYD genotype (Other); Therapeutic drug monitoring of 5FU (Other)

Phase: Phase 4

Status: Recruiting

Sponsored by: Cantonal Hospital of St. Gallen

Official(s) and/or principal investigator(s):
Markus Joerger, MD PhD, Study Chair, Affiliation: Cantonal Hospital St.Gallen (Switzerland)

Overall contact:
Markus Joerger, MD PhD, Phone: (0)76-5591070, Ext: +41, Email: markus.joerger@gmail.com


The fluoropyrimidines 5-fluorouracil (5FU) and capecitabine (Cp) are among the most commonly used anticancer drugs. Still, there is much controversy about the correct dosing, and the fact that a minority of patients experience severe, sometimes even lethal toxicity following treatment. One important factor predisposing patients to severe toxicity is deficiency in the 5FU-catabolic enzyme dihydropyrimidine dehydrogenase (DPD). Our group identified 4 DPD risk alleles in over 300 Swiss cancer patients, that resulted in a 8-times increased risk of experiencing severe toxicity from 5FU or Cp. In patients receiving 5FU as a continuous infusion, there are accumulating data that keeping the AUC of 5FU between 20-30 mg*h/L is beneficial in terms of treatment toxicity and activity. In this study, patients carrying at least 1/4 DPD risk alleles will receive a 50% dose reduction of either 5FU or Cp, with the potential of later dose increases in the abscence of severe toxicity. Additionally, patients receiving i. v. 5FU will undergo therapeutic drug monitoring at the end of the 2-day continuous infusion, with subsequent dose adaptations to target a 5FU AUC of 20-30 mg*h/L. The primary study objective is to reduce the incidence of severe treatment-related toxicity from 13% (in historical controls) to 5% in study patients.

Clinical Details

Official title: Pharmacogenetics and Therapeutic Drug Monitoring for the Optimization of Fluoropyrimidine Treatment in Patients With Advanced Colorectal Cancer

Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Predefined fluoropyrimidine-related (index) toxicity

Secondary outcome:

Area-under-the plasma-concentration time curve of 5-fluorouracil

Endogenous dihydrouracil/uracil ratio in plasma

Objective treatment response (best response) according to RECIST v.1.1

Progression-free survival


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Cytological or histological proven diagnosis of colorectal cancer, metastatic or

inoperable advanced disease, not amenable to curative therapy

- Measurable disease, defined as at least one lesion (outside of irradiated areas) that

can be measured in at least one dimension as ≥ 10 mm (≥ 15 mm in case of lymph nodes) according to RECIST v1. 1

- Tumor either wild-type KRAS or KRAS-mutated

- Indication for the therapeutic use of continuous intravenous 5FU over 48 hours

("deGramont" regimen) or oral Cp, either alone or in combination with other anticancer drugs (including monoclonal antibodies or other molecularly-targeted drugs)

- Eligible treatment regimens include: FOLFOX (FOLFOX 4, FOLFOX 6, modified FOLFOX 6,

FOLFOX 7), FOLFIRI, 5FU or Cp mono-chemotherapy ("deGramont" regimen), XELOX, XELIRI, Capecitabine mono-chemotherapy

- All regimens may be combined with anti-VEGF or anti-EGFR targeted treatment such as

bevacizumab or cetuximab

- Patients receive first-line systemic treatment (previous adjuvant chemotherapy is

allowed, previous rectal radiochemotherapy is allowed if completed >/=1 months before registration to the study)

- Written informed consent before registration to the trial

- The patient is willing to undergo pharmacogenetic and pharmacokinetic sampling and


- WHO performance status 0 or 1

- Female or male patients >18 years of age

- Adequate organ function (ANC, PLT, bilirubin 2xULN, creatinine clearance)

Exclusion Criteria:

- Known hypersensitivity to trial drug or any compounds of the drug

- Pregnant or breastfeeding women

- Patients with cerebral and/or leptomeningeal metastases are eligible, unless there is

a need for treatment with steroids

- Risk of rapid deterioration due to tumor symptoms or tumor complications

- Severe or uncontrolled cardiovascular disease (e. g. ACS, cardiac failure NYHA III or

IV, clinically relevant myopathy, history of myocardial infarction within the last 12 months, significant arrhythmias)

- Concurrent use of reversible or irreversible DPD-inhibitors, including brivudin,

sorivudin, eniluracil 5-chloro-2,4-dihydroxypyridine or with substances interfering with the immunoassay, including theophylline and theobromine.

- Concurrent severe uncontrolled medical illness (judged by the investigator) which

could impair the ability of the patient to participate in the trial

Locations and Contacts

Markus Joerger, MD PhD, Phone: (0)76-5591070, Ext: +41, Email: markus.joerger@gmail.com

Inselspital, Bern 3010, Switzerland; Not yet recruiting
Carlo Largiadèr, PhD, Phone: (0)31-6322111, Ext: +41, Email: carlo.largiader@insel.ch
Carlo Largiader, PhD, Principal Investigator

Cantonal Hospital, St.Gallen 9007, Switzerland; Recruiting
Markus Joerger, MD PhD, Phone: (0)76-5591070, Ext: +41, Email: markus.joerger@gmail.com
Markus Joerger, MD PhD, Principal Investigator

Additional Information

Starting date: October 2012
Last updated: August 31, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017